{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:43:33Z","timestamp":1788587013857,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jtho.2020.01.012","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T16:34:49Z","timestamp":1580229289000},"page":"843-859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression"],"prefix":"10.1016","volume":"15","author":[{"given":"Daniel","family":"Rathkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manakamana","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjistha","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Jung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Filie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Raffeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2020.01.012_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jtho.2020.01.012_bib2","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2020.01.012_bib3","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2020.01.012_bib5","doi-asserted-by":"crossref","first-page":"10493","DOI":"10.1016\/S0021-9258(19)70490-6","article-title":"ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA","volume":"255","author":"Benjamin","year":"1980","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtho.2020.01.012_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/283593a0","article-title":"(ADP-ribose)n participates in DNA excision repair","volume":"283","author":"Durkacz","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2020.01.012_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2020.01.012_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2020.01.012_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140988","article-title":"Combinations of PARP inhibitors with temozolomide drive PARP1 trapping and apoptosis in Ewing\u2019s sarcoma","volume":"10","author":"Gill","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2020.01.012_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-14-2572","article-title":"Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program","volume":"21","author":"Smith","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2407-14-151","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide","volume":"14","author":"Tentori","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2020.01.012_bib13","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2020.01.012_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12967-018-1559-7","article-title":"Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members","volume":"16","author":"Kittaneh","year":"2018","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2020.01.012_bib15","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.01.012_bib16","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A\u00a0subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","author":"Pastorino","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.01.012_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2020.01.012_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.01.012_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2020.01.012_bib20","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","article-title":"BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization","volume":"68","author":"Ventii","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib21","doi-asserted-by":"crossref","first-page":"10292","DOI":"10.1038\/ncomms10292","article-title":"BAP1\/ASXL1 recruitment and activation for H2A deubiquitination","volume":"7","author":"Sahtoe","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2020.01.012_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12013-011-9184-6","article-title":"An emerging model for BAP1\u2019s role in regulating cell cycle progression","volume":"60","author":"Eletr","year":"2011","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.jtho.2020.01.012_bib23","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1128\/MCB.00396-10","article-title":"The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression","volume":"30","author":"Yu","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jtho.2020.01.012_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib25","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2020.01.012_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca(2+) flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2020.01.012_bib28","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2020.01.012_bib29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/0008-5472.CAN-16-2983","article-title":"Temozolomide in the era of precision medicine","volume":"77","author":"Thomas","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12885-015-1362-2","article-title":"Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma","volume":"15","author":"Kalra","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2020.01.012_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neo.2015.03.004","article-title":"Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors","volume":"17","author":"Hovelson","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.jtho.2020.01.012_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.isci.2018.11.029","article-title":"CellMinerCDB for integrative cross-database genomics and pharmacogenomics analyses of cancer cell lines","volume":"10","author":"Rajapakse","year":"2018","journal-title":"iScience"},{"key":"10.1016\/j.jtho.2020.01.012_bib33","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acssynbio.6b00343","article-title":"sgRNA Scorer 2.0: a species-independent model to predict CRISPR\/Cas9 activity","volume":"6","author":"Chari","year":"2017","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.jtho.2020.01.012_bib34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.jtho.2020.01.012_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.jtho.2020.01.012_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/jpet.113.210146","article-title":"Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition","volume":"349","author":"Murai","year":"2014","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jtho.2020.01.012_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2020.01.012_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1741-7007-7-23","article-title":"Noisy splicing, more than expression regulation, explains why some exons are subject to nonsense-mediated mRNA decay","volume":"7","author":"Zhang","year":"2009","journal-title":"BMC Biol"},{"key":"10.1016\/j.jtho.2020.01.012_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2020.01.012_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","article-title":"SLFN11 blocks stressed replication forks independently of ATR","volume":"69","author":"Murai","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.jtho.2020.01.012_bib41","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2020.01.012_bib42","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-15-0335","article-title":"Using CellMiner 1.6 for systems pharmacology and genomic analysis of the NCI-60","volume":"21","author":"Reinhold","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040062","article-title":"Concordance of gene expression and functional correlation patterns across the NCI-60 cell lines and the Cancer Genome Atlas glioblastoma samples","volume":"7","author":"Zeeberg","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2020.01.012_bib44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jtho.2020.01.012_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-cancerbio-030518-055914","article-title":"PARP trapping beyond homologous recombination and platinum sensitivity in cancers","volume":"3","author":"Murai","year":"2019","journal-title":"Annu Rev Cancer Biol"},{"key":"10.1016\/j.jtho.2020.01.012_bib46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.jtho.2020.01.012_bib47","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","article-title":"MGMT testing--the challenges for biomarker-based glioma treatment","volume":"10","author":"Wick","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jtho.2020.01.012_bib48","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","article-title":"Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker","volume":"18","author":"Pietanza","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib49","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.01.012_bib50","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0959-8049(01)00428-2","article-title":"A\u00a0phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma","volume":"38","author":"van Meerbeeck","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.01.012_bib51","first-page":"69","article-title":"Genomic instability and tolerance to alkylating agents","volume":"28","author":"Karran","year":"1996","journal-title":"Cancer Surv"},{"key":"10.1016\/j.jtho.2020.01.012_bib52","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/0008-5472.CAN-16-1151","article-title":"DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme","volume":"77","author":"Nagel","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.01.012_bib53","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.01.012_bib54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pe\u00f1a-Llopis","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2020.01.012_bib55","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1534\/g3.114.013482","article-title":"The genome of the chicken DT40 bursal lymphoma cell line","volume":"4","author":"Moln\u00e1r","year":"2014","journal-title":"G3 (Bethesda)"},{"key":"10.1016\/j.jtho.2020.01.012_bib56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.aav4902","article-title":"Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1","volume":"364","author":"He","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.01.012_bib57","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2020.01.012_bib58","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420300356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420300356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:43:44Z","timestamp":1761561824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086420300356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1556086420300356"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2020.01.012","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2020.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}